

Preliminary In Vitro Evaluation of an Adjunctive Therapy for Extremity Wound Infection Reduction: Rapidly Resorbing Local Antibiotic Delivery

Stephanie R. Jackson,¹ Kelly C. Richelsoph,¹ Harry S. Courtney,² Joseph C. Wenke,³ Joanna G. Branstetter,³ Joel D. Bumgardner,¹ Warren O. Haggard¹

¹Joint Program in Biomedical Engineering, The University of Memphis and The University of Tennessee, Herff College of Engineering, 330 Engineering Technology Building, Memphis, Tennessee 38152-3210, ²Veterans Affairs Medical Center and Department of Medicine, University of Tennessee, Memphis, Tennessee 38104, ³U.S. Army Institute of Surgical Research, Fort Sam Houston, Texas 78234

Received 22 July 2008; accepted 7 November 2008

Published online 22 December 2008 in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jor.20828

ABSTRACT: Despite the continuing advances in treatment of open fractures and musculoskeletal wounds, infection remains a serious complication. Current treatments to prevent infection utilize surgical debridement and irrigation, and high doses of systemic antimicrobial therapy. The aim of this work was to evaluate, in vitro, the potential of a fast-resorbing calcium sulfate pellet loaded with an antibiotic. The pellet could be used as an adjunctive therapy at the time of debridement and irrigation to reduce bacterial wound contamination. Small pellets containing a binder and calcium sulfate were engineered to resorb rapidly (within 24 h) and deliver high local doses of antibiotic (amikacin, gentamicin, or vancomycin) to the wound site while minimizing systemic effects. Results from dissolution, elution, and biological activity tests against *P. aeruginosa* and *S. aureus* were used to compare the performance of antibiotic-loaded, rapidly resorbing calcium sulfate pellets to antibiotic-loaded crushed conventional calcium sulfate pellets. Antibiotic-loaded rapidly resorbing pellets dissolved in vitro in deionized water in 12–16 h and released therapeutic antibiotic levels in phosphate buffered saline that were above the minimal inhibitory concentration for *P. aeruginosa* and *S. aureus*, completely inhibiting the growth of these bacteria for the life of the pellet. Crushed conventional calcium sulfate pellets dissolved over 4–6 days, but the eluates only contained sufficient antibiotic to inhibit growth for the first 4 h. These data indicate that fast-resorbing pellets can release antibiotics rapidly and at therapeutic levels. Adjunctive therapy with fast-acting pellets is promising and warrants further in vivo studies. © 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. *J Orthop Res* 27:903–908, 2009

Keywords: drug delivery; calcium sulfate; infection; musculoskeletal trauma; bioresorbable

Infection remains a serious complication despite continuing advances in the treatment of complex musculoskeletal trauma. The emergence of bacteria resistance to traditional antibiotic therapies further complicates the treatment of these injuries.¹ Since U.S. military operations began in Afghanistan and Iraq, wound contamination with resistant bacteria has increased the occurrence of osteomyelitis and nosocomial infections in military hospitals.¹ To decrease the potential for wound infection, the current standard of care involves removal of all foreign material and necrotic tissue followed by irrigation and systemic antibiotic therapy.^{2–4} High concentrations of systemic antibiotic are required to attain sufficient local levels in contaminated tissues with compromised vascularization. In the most difficult cases, multiple debridements and prolonged antibiotic therapy are required over several weeks to complete treatment.^{4,5} Antibiotic toxicity, side effects, and evolution of bacterial resistance are problems associated with this course of therapy.^{5,6}

Local delivery systems that place antibiotics directly at the contamination site are favorable alternatives or adjuncts because they minimize systemic toxicity and eliminate concerns about antibiotic penetration.^{7–9} A local system capable of delivering antibiotics between debridement procedures could help reduce the incidence of infection in musculoskeletal trauma. Use of biodegradable drug delivery systems evades the need for

additional surgery required by nonresorbable systems, such as polymethylmethacrylate (PMMA) beads.^{6,10,11}

Calcium sulfate, a biocompatible, biodegradable material, is an interesting candidate for local delivery in cases of trauma because extensive bone damage is common. Calcium sulfate improves bone healing and repair, even when loaded with an antibiotic.^{12,13} Calcium sulfate, optimized to resorb at a rate similar to that of new bone formation (several weeks to months) has been combined with antibiotics to eradicate existing bone infections in clinical and experimental situations.^{2,5,7–9,13–16} A calcium sulfate pellet, engineered to dissolve and elute antibiotic over a shorter period of time, may be advantageous for infection prevention.

The concept of preventing infection by a more rapid dissolution of calcium sulfate and a faster antibiotic elution was investigated by Yarbboro et al.⁷ Conventional calcium sulfate pellets loaded with gentamicin (128 mg gent/g) and then crushed into flakes were applied to a *S. aureus* contaminated rat femur defect. They found no improvement in infection prevention over systemic antibiotic administration, but they found a significant improvement over systemic antibiotics with a local injection of gentamicin. They speculated that no improvement was observed over systemic gentamicin with calcium sulfate flake treatment because the sustained presence of calcium sulfate provided a substrate for bacterial adhesion. They also speculated that lower peak concentrations were seen with delivery from the flakes, which may explain why local gentamicin injection was superior to systemic antibiotics or calcium sulfate flakes.⁷

Correspondence to: Warren O. Haggard (T: 901-678-4346; F: 901-678-5281; E-mail: whaggrd1@memphis.edu)

© 2008 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.

Report Documentation Page				Form Approved OMB No. 0704-0188	
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.					
1. REPORT DATE 01 JUL 2009		2. REPORT TYPE N/A		3. DATES COVERED -	
4. TITLE AND SUBTITLE Preliminary in vitro evaluation of an adjunctive therapy for extremity wound infection reduction: rapidly resorbing local antibiotic delivery				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Jackson S. R., Richelsoph K. C., Courtney H. S., Wenke J. C., Branstetter J. G., Bumgardner J. D., Haggard W. O.,				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) United States Army Institute of Surgical Research, JBSA Fort Sam houston, TX 78234				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 6	19a. NAME OF RESPONSIBLE PERSON
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified			

We hypothesized that a pellet can be loaded with an antibiotic, such as amikacin, gentamicin, or vancomycin, and made to dissolve and release local therapeutic levels of antibiotic within 24 h. Our long-range goal is to administer these rapidly resorbing pellets (FAST pellets) during initial debridement and irrigation, concurrently with systemic antibiotics, to reduce the level of bacterial contamination and the potential for infection in complex musculoskeletal injury. The use of calcium sulfate dihydrate and a binder gives these pellets their unique dissolution properties, since the pellets contain much larger and less tightly interconnected crystals than conventional pellets cast from alpha-hemihydrate.¹⁷ The in vitro performance of the FAST pellet was also compared to crushed gentamicin-loaded conventional calcium sulfate pellets, similar to the concept employed by Yarboro et al.⁷

METHODS

Manufacture of Rapidly Resorbing Pellets

Antibiotic-loaded FAST pellets were made by mixing 10.0 g Food and Pharmaceutical grade calcium sulfate dihydrate powder (Terra Alba; US Gypsum, Chicago, IL) with 0.40 g sodium carboxymethylcellulose (CMC; Hercules, Wilmington, DE). A solution was prepared by mixing an antibiotic [0.42 g amikacin (amikacin sulfate; Bedford Labs., Bedford, OH), gentamicin (gentamicin sulfate; MP Biomedicals, Solon, OH), or 0.43 g vancomycin (vancomycin hydrochloride; Acros, Morris Plains, NJ) with 8.4 g deionized (DI) water. The solution was poured over the Terra Alba and CMC powders, and then the materials were mixed briskly for 1 min. The resulting 4% antibiotic-loaded paste was cast into silicone elastomer molds and allowed to dry for 24 h at room temperature. Once dry, the cylindrically shaped pellets (4.7 mm height, 3.4 mm diameter, 40 ± 2 mg weight) were demolded and sterilized using low-dose gamma irradiation (25 kGy) (Steris Isomedics, Libertyville, IL). Control pellets (calcium sulfate and CMC only) were cast using the same procedure. Pellets were characterized for calcium sulfate crystallinity by X-ray diffraction and differential scanning calorimetry, and overall morphology by SEM (Fig. 1).

Manufacture of Conventional Calcium Sulfate Pellets

Conventional calcium sulfate alpha-hemihydrate gentamicin pellets were cast by mixing 1.04 g gentamicin sulfate powder (gentamicin sulfate; MP Biomedicals) with 5.0 g DI water. The antibiotic solution was poured over 20.0 g calcium sulfate alpha-hemihydrate (calcium sulfate hemihydrate; Wright Medical Technology, Arlington, TN), and mixed briskly for 1 min.^{9,14,18,19} The resulting 4% antibiotic-loaded paste was cast into silicone elastomer molds and left to dry overnight at room temperature. The pellets were then demolded and sterilized again using low-dose gamma irradiation (25 kGy). Each pellet was again 4.7 mm high, 3.4 mm diameter, and weighed 105 ± 4 mg. The pellets were crushed using a mortar and pestle into fine- and coarse-sized flakes; fine flake diameter was 150 μ m (range, 0–300 μ m), while coarse flake diameter was 600 μ m (range, 0–1,200 μ m). Flake size was verified using an inverting light microscope and image processing software (Bioquant Osteo II, Bioquant Image Analysis, Nashville, TN).




Figure 1. Environmental (Wet) Mode SEM images of (A) sterile conventional calcium sulfate pellet flakes or (B) FAST calcium sulfate pellets loaded with 4% gentamicin (original magnification, $\times 1000$).

Dissolution Testing

To evaluate dissolution of the FAST pellets, individual pellets or the equivalent of one pellet in flakes ($n \geq 3$) were immersed in 100 ml of DI water in a 37°C water bath. At 1, 4, 8, 12, 24, 36, 48, 72, 96, 120, and 144 h, pellets were removed, oven dried at 37°C for 1 h, and weighed. The pellets were then reimmersed in fresh DI water. Testing continued until pellets were completely dissolved. Testing was repeated for three batches of pellets.

Elution Testing

Elution was characterized by placing groups of eight pellets or the flakes of eight pellets ($n \geq 3$) in 20 ml phosphate buffered saline (PBS) in a 37°C water bath. At 1, 4, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, and 240 h, aliquots were removed and frozen at -40°C . At each time point, the pellets were removed and placed in 20 ml fresh PBS. The amount of antibiotic in the eluates was determined ($\mu\text{g/ml}$) using a Fluorescence Polarization Immunoassay (TDxFLx; Abbott Laboratories, Abbott Park, IL). Testing was repeated for three batches of pellets.

Biological Activity Testing

Pseudomonas aeruginosa strain ATCC 27317 was used for biological activity testing of amikacin and gentamicin eluates.

A clinical isolate of *Staphylococcus aureus* Cowan I strain was used to assess activity of vancomycin eluates. The eluate having the lowest concentration for each antibiotic at each of the specified time points was used in the biological activity assay. *P. aeruginosa* and *S. aureus* were grown overnight at 37°C in trypticase soy broth (TSB). Conical tubes were prepared with 1.75 ml of TSB and 200 µl of antibiotic dilutions (amikacin: 0–640 µg/ml; gentamicin: 0–2,560 µg/ml; vancomycin: 0–160 µg/ml), 200 µl eluate samples, or 200 µl buffer. All tubes, except blanks, were inoculated with 50 µl of 1:50 dilution of bacteria. Blanks were supplanted with an additional 50 µl of TSB instead of bacteria. The tubes were vortexed and incubated at 37°C for 24 h. A blank was used to adjust the spectrophotometer to zero, and the absorbance at 530 nm (A_{530}) was recorded. Results were reported as percent growth relative to control, calculated as $(A_{530} \text{ sample}/A_{530} \text{ control}) \times 100$. This method diluted the sample concentration by a factor of 10. Testing was repeated for three replicates of the samples.

Statistics

Statistical analyses included two-factor ANOVA and multiple comparisons tests with significance set at $\alpha = 0.05$. For FAST pellets, differences in the dissolution or elution rate based on the antibiotic incorporated were evaluated. Gentamicin-loaded FAST pellets were compared to conventional pellet flakes by analyzing differences in dissolution or elution rate based on treatment type (FAST pellet, fine flakes, or coarse flakes).

RESULTS

Dissolution Testing

Sterile FAST pellets dissolved completely between 12–16 h (Fig. 2). Significant differences were only observed in the dissolution rates of gentamicin- and vancomycin-loaded pellets ($p < 0.01$), with gentamicin-loaded pellets dissolving more rapidly than vancomycin-loaded pellets. In general, for all antibiotics, 50%–70% of the pellet was dissolved within 4 h, 85%–90% within 8 h, more than 95% within 12 h, and no pellet remained after 16 h.

The dissolution rates were significantly different for fine and coarse conventional calcium sulfate pellet flakes ($p < 0.001$). Coarse- and fine-sized conventional




Figure 2. Dissolution of sterile FAST calcium sulfate pellets loaded with 4% amikacin, gentamicin, or vancomycin.




Figure 3. Dissolution profile comparison for gentamicin-loaded FAST pellets and gentamicin-loaded conventional calcium sulfate pellet flakes crushed into fine or coarse size.

gentamicin-loaded calcium sulfate pellet flakes dissolve in 4–6 days. Over 50% of the flake mass dissolved in 12 h for fine flakes and in 24 h for coarse flakes (Fig. 3).

Elution Testing

Differences were found in elution rates for vancomycin/amikacin ($p = 0.04$), but not for amikacin/gentamicin and vancomycin/amikacin (Fig. 4). Qualitatively, the elution profiles for gentamicin and amikacin both peaked at 1 h and decreased exponentially over the life of the pellets. The vancomycin elution profile showed a burst of antibiotic in the first hour, followed by a smaller release at hour 2, another burst at 4 and 8 h, and a relatively stable decrease for the remaining life of the pellet.

The elution rate for coarse and fine pellet flakes differed ($p < 0.001$) only over the first 4 h (Fig. 5). Similar elution profiles were found for coarse flakes and FAST gentamicin pellets for the first 24 h ($p = 0.740$). Elution beyond 24 h was not compared, since the FAST resorbing pellet sample had completely dissolved by this time point.




Figure 4. Elution of antibiotics from sterile FAST calcium sulfate pellets loaded with 4% amikacin, gentamicin, or vancomycin.




Figure 5. Elution profile comparison for gentamicin-loaded FAST pellets and gentamicin-loaded conventional calcium sulfate pellet flakes crushed to fine or coarse size.

Biological Activity Testing

The observed minimum inhibitory concentration (MIC) of *P. aeruginosa* ATCC 27317 treated with amikacin or gentamicin was 4.0 µg/ml (Table 1), within the range of the published literature.²⁰ Both gentamicin- and amikacin-loaded FAST pellet eluates completely inhibited growth of *P. aeruginosa* for 1, 2, and 4 h, as they maintained antibiotic concentration above the MIC. The MIC for *S. aureus* Cowan I clinical isolate with vancomycin was 0.5 µg/ml, within the range of the published literature.²¹ Vancomycin-loaded FAST pellets were active against *S. aureus* through 12 h. At 24 h, the vancomycin concentration fell below the MIC. For both coarse- and fine-flake experiments, only the hour 1 sample contained sufficient antibiotic to inhibit growth of *P. aeruginosa*.

DISCUSSION

In recent years, calcium sulfate has been used extensively in local drug delivery, and has been effective in

clinically treating chronic osteomyelitis when impregnated with tobramycin.^{2,5,7–9,13–16,19} We evaluated the dissolution, elution, and biological activity of fast-degrading drug delivery vehicles made from cellulose binder and calcium sulfate dihydrate and from conventional calcium sulfate alpha-hemihydrate crushed into flakes. While this study used the Yarbboro-type crushed conventional cast antibiotic-loaded calcium sulfate pellet as a comparison, the crushing/compressing of commercially available calcium sulfate pellets with tobramycin is not recommended by the manufacturer.²² Our ultimate goal was to assess the potential of these two calcium sulfate-based carriers to reduce the incidence of infection in contaminated wounds by measuring their ability to release high concentrations of antibiotic shortly after administration in an in vitro environment.

Any new delivery vehicle should be versatile, since elution rate depends upon the interaction of carrier and antibiotic^{23,24} and since emerging bacterial resistance is causing physicians to reconsider traditional antibiotic therapies.^{20,21,25–28} We demonstrated that amikacin, gentamicin, or vancomycin can be delivered from the calcium sulfate dihydrate FAST pellets with effective dissolution and elution profiles. All FAST pellet formulations completely dissolved and eluted antibiotics in 12–24 h, whereas only 50% of the conventional pellet flakes had dissolved and 99.3% of antibiotic was released within this time frame. Variations in the crystal structure, and therefore, surface area, allows for the different dissolution profiles of these two delivery systems.^{17,18,29}

The dissolution rate of the conventional calcium sulfate pellet was not substantially affected by the act of crushing, but its antibiotic elution was affected. The largest burst of antibiotic (1,278 µg/ml fine flakes with 96% of antibiotic loading or 945 µg/ml coarse flakes with 85% of antibiotic loading) occurred at 1 h, and then sub-MIC levels were released after 4 h for fine flakes and 8 h for coarse flakes for more than 15 days. Similar research

Table 1. Biological Activity Testing Results

Timepoint (h)	Organism				
	<i>S. aureus</i> Cowan I		<i>P. aeruginosa</i> ATCC 27317		
	RR+Vanc	RR+Amik	RR+Gent	CF+Gent	FF+Gent
1	–	–	–	–	–
2	–	–	–	+	+
4	–	–	–	+	+
8	–	+	+	+	+
12	–	+	+	+	+
24	+	+	+	+	+
48	+	+	+	+	+
240	/	/	/	+	+

RR, rapidly resorbing calcium sulfate pellet; Vanc, vancomycin; Amik, amikacin; Gent, gentamicin; CF, coarse conventional calcium sulfate pellet flakes; FF, fine conventional calcium sulfate pellet flakes; –, no growth; +, growth.

on the conventional, uncrushed pellets, which are designed to elute antibiotic over a period of 28 days and used clinically to eradicate an existing infection, release concentrations of roughly 1,000 µg/ml/g over the first 24 h and 10 µg/ml/g over the next 24 h, sufficient levels to prevent antibiotic growth for weeks.^{9,14,18,28,29} With such immediate antibiotic elution from conventional flakes, the in vitro work of this study does not suggest that a large difference in initial antibiotic concentration would occur between flakes and an injection.⁷

Comparing the characteristics for the FAST pellet and the conventional flakes by Yarbboro, we found that the FAST pellet dissolved more quickly and eluted antibiotic at a more sustained rate. This observation may pose a clinical advantage for administration of the FAST pellet in traumatic injuries. Our findings suggest that sufficient antibiotic concentrations are maintained to inhibit the growth of susceptible organisms for the life of the pellet. Just as conventional calcium sulfate pellets remain cohesive with up to 12% by weight of antibiotic loading,²⁹ the antibiotic loading of the FAST pellet could be adjusted to deliver higher antibiotics levels that may be required to target resistant organisms with MICs higher than those used in this study.

The limitations of our study arise from differences between in vitro and in vivo environments. In vitro data is an essential screening tool for new biomaterials. In measuring the drug release from a biomaterial, in vitro data can be used to compare different types of drug delivery systems. If one system was found to release more quickly than another, it would be expected that this difference would hold true in vivo, although the absolute rate of release may vary from an in vivo environment. Additional in vivo investigations are planned to determine if the in vitro findings of this study correlate to reduced risk of infection, biofilm formation, patient morbidity, and patient mortality in cases of complex musculoskeletal trauma.^{7,30-36}

ACKNOWLEDGMENTS

This study was funded by the U.S. Army (OTRP W81XWH-07-0206). Special thanks to Dr. Mark Smeltzer and Sonja Daily (University of Arkansas School of Medicine, Little Rock, AR), Lou Boykins (Electron Microscopy Center, University of Memphis, Memphis, TN), Dr. Sanjay Mishra (Department of Physics, University of Memphis, Memphis, TN), and Linda Morris and Ann Burgess (Wright Medical Technology, Arlington, TN).

REFERENCES

1. Spinner J. 2007. Resilient infections worry military doctors. *The Washington Post*, p B01.
2. Carek PJ, Dickerson LM, Sack JL. 2001. Diagnosis and management of osteomyelitis. *Am Fam Physician* 63:2413-2420.
3. Gustilo RB, Anderson JT. 1976. Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses. *J Bone Joint Surg [Am]* 58:453-458.
4. Svoboda SJ, Bice TG, Gooden HA, et al. 2006. Comparison of bulb syringe and pulsed lavage irrigation with use of a

- bioluminescent musculoskeletal wound model. *J Bone Joint Surg [Am]* 88:2167-2174.
5. Thomas DB, Brooks DE, Bice TG, et al. 2005. Tobramycin-impregnated calcium sulfate prevents infection in contaminated wounds. *Clin Orthop Relat Res* 441:366-371.
6. Neut D, van de Belt H, van Horn JR, et al. 2003. Residual gentamicin-release from antibiotic-loaded polymethylmethacrylate beads after 5 years of implantation. *Biomaterials* 24:1829-1831.
7. Yarbboro SR, Baum EJ, Dahners LE. 2007. Locally administered antibiotics for prophylaxis against surgical wound infection: an in vivo study. *J Bone Joint Surg [Am]* 89:929-933.
8. Nelson CL, McLaren SG, Skinner RA, et al. 2002. The treatment of experimental osteomyelitis by surgical debridement and the implantation of calcium sulfate tobramycin pellets. *J Orthop Res* 20:643-647.
9. McKee M. 2002. The use of an antibiotic impregnated, osteoconductive, bioabsorbable bone substitute in the treatment of infected long bone defects: early results of a prospective trial. *J Orthop Trauma* 16:1218-1224.
10. Kanellakopoulou K, Giamarellos-Bourboulis EJ. 2000. Carrier systems for the local delivery of antibiotics in bone infections. *Drugs* 59:1223-1232.
11. Ashammakhi N, Suuronen R, Tiainen J. 2003. Spotlight on naturally absorbable osteofixation devices. *J Craniofac Surg* 14:247-259.
12. Turner TM, Urban RM, Gitelis S, et al. 1999. Efficacy of calcium sulfate, a synthetic bone graft material, in healing a large canine medullary defect. *Trans Orthop Res Soc* 24:552.
13. Turner TM, Urban RM, Gitelis S, et al. 2001. Radiographic and histologic assessment of calcium sulfate in experimental animal models and clinical use as a resorbable bone-graft substitute, a bone-graft expander, and a method for local antibiotic delivery: one institution's experience. *J Bone Joint Surg [Am]* 83-A(Suppl 2):8-18.
14. Gitelis S, Brebach GT. 2002. The treatment of chronic osteomyelitis with a biodegradable antibiotic-impregnated implant. *J Orthop Surg (Hong Kong)* 10:53-60.
15. Papagelopoulos PJ, Mavrogenis AF, Tsiodras S, et al. 2006. Calcium sulphate delivery system with tobramycin for the treatment of chronic calcaneal osteomyelitis. *J Int Med Res* 34:704-712.
16. Wenke JC, Owens BD, Svoboda SJ, et al. 2006. Effectiveness of commercially-available antibiotic-impregnated implants. *J Bone Joint Surg [Br]* 88:1102-1104.
17. Taylor HFW. 1997. *Cement chemistry*, 2nd ed. London: Academic Press; 480 p.
18. Sharma S. 2006. Enhancing calcium sulfate antibiotic delivery through a composite approach. Memphis, TN: The University of Memphis.
19. Wright Medical Technology. 1998. Technical monograph on Osteoset®-T. Arlington, TN: Wright Medical Technology.
20. Endimiani A, Luzzaro F, Pini B, et al. 2006. *Pseudomonas aeruginosa* bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase. *BMC Infect Dis* 6:52.
21. Schwalbe RS, Stapleton JT, Gilligan PH. 1987. Emergence of resistance in coagulase negative staphylococci. *N Engl J Med* 316:927-931.
22. Wright Medical Technology. September 2006. OSTEOSSET® T bone graft products, Wright Medical Technology package insert 130764-1. Arlington, TN: Wright Medical Technology.
23. Mousset B, Benoit MA, Delloye C, et al. 1995. Biodegradable implants for potential use in bone infection. *Int Orthop* 19:157-161.

24. Wichelhaus TA, Dingeldein E, Rauschmann M, et al. 2001. Elution characteristics of vancomycin, teicoplanin, gentamicin, and clindamycin from calcium sulfate beads. *J Antimicrob Chemother* 48:117–119.
25. Drago L, De Vecchi E, Nicola L, et al. 2005. In vitro selection of resistance in *Pseudomonas aeruginosa* and *Acinetobacter* spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin. *J Antimicrob Chemother* 56:353–359.
26. Shigeharu O, Toshinari U, Akihiro S, et al. 2003. In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant *Pseudomonas aeruginosa*. *J Antimicrob Chemother* 52:911–914.
27. Oie S, Sawa A, Kamiya A, et al. 1999. In-vitro effects of a combination of antipseudomonal antibiotics against multidrug resistant *Pseudomonas aeruginosa*. *J Antimicrob Chemother* 44:689–691.
28. Cavallo J, Fabre R, Leblanc F, et al. 2000. Antibiotic susceptibility and mechanisms of beta-lactam resistance in 1310 strains of *Pseudomonas aeruginosa*: a French multicentre study (1996). *J Antimicrob Chemother* 46:133–136.
29. Richelsoph K, Petersen D, Haggard W, et al. 1998. Elution characteristics of tobramycin-impregnated medical grade calcium sulfate hemihydrate. *Trans Orthop Res Soc* 44:429.
30. Stewart PS, Costerton JW. 2001. Antibiotic resistance of bacteria in biofilms. *Lancet* 358:135–138.
31. Donlan RM. 2002. Biofilms: microbial life on surfaces. *Emerg Infect Dis* 8:881–890.
32. Sarkisova S, Patrauchan MA, Berglund D, et al. 2005. Calcium-induced virulence factors associated with the extracellular matrix of mucoid *Pseudomonas aeruginosa* biofilms. *J Bacteriol* 187:4327–4337.
33. Turakhia MH, Characklis WG. 2004. Activity of *Pseudomonas aeruginosa* in biofilms: effect of calcium. *Biotechnol Bioeng* 33:406–414.
34. Lewis K. 2001. Riddle of biofilm resistance. *Antimicrob Agents Chemother* 45:999–1007.
35. Steckelberg JM, Osmon DR. 2000. Prosthetic joint infection. In: Waldvogel FA, Bisno AL, editors. *Infections associated with indwelling medical devices*, 3rd ed. Washington, DC: American Society for Microbiology Press, p 173–209.
36. Anglen JO. 2001. Wound irrigation in musculoskeletal injury. *J Am Acad Orthop Surg* 9:219–226.